Presentation is loading. Please wait.

Presentation is loading. Please wait.

FIGURE 1 Flow chart of patient enrollment and exclusion

Published byMiles Elliott Modified over 6 years ago

Similar presentations

Presentation on theme: "FIGURE 1 Flow chart of patient enrollment and exclusion"— Presentation transcript:

1 FIGURE 1 Flow chart of patient enrollment and exclusion
FIGURE 1 Flow chart of patient enrollment and exclusion. Among the 1268 enrolled patients, 378 patients were excluded ... FIGURE 1 Flow chart of patient enrollment and exclusion. Among the 1268 enrolled patients, 378 patients were excluded for the analysis at M6 because of lack of PTH value; moreover, 80 patients in this group were no longer taking cinacalcet-HCl at M6. At M12, another additional group of 95 was excluded for the same reason, and among them 130 patients were not taking cinacalcet-HCl. Overall, we identified 652 patients who could be analysed at the end of the 36 month period of the study. EOS, end of study. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Clin Kidney J, sfz021, The content of this slide may be subject to copyright: please see the slide notes for details.

2 FIGURE 2 Odds ratios of factors associated with the response to cinacalcet-HCl. Multivariate analysis showing the odds ... FIGURE 2 Odds ratios of factors associated with the response to cinacalcet-HCl. Multivariate analysis showing the odds ratios [95% confidence interval (CI)] of the factors that remained associated with uncontrolled SHPT after 12 months of treatment by cinacalcet-HCl were younger age and higher baseline serum calcium and PTH levels. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Clin Kidney J, sfz021, The content of this slide may be subject to copyright: please see the slide notes for details.

3 FIGURE 3 PTH course during the study
FIGURE 3 PTH course during the study. This figure shows the course of mean serum PTH levels, and the number of ... FIGURE 3 PTH course during the study. This figure shows the course of mean serum PTH levels, and the number of patients at each time point, during the 3-year follow-up for the 1268 patients included in the analysis. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Clin Kidney J, sfz021, The content of this slide may be subject to copyright: please see the slide notes for details.

4 FIGURE 4 Four different PTH trajectories
FIGURE 4 Four different PTH trajectories. This figure shows the course of mean serum PTH levels for four different ... FIGURE 4 Four different PTH trajectories. This figure shows the course of mean serum PTH levels for four different groups of patients: those who were rapidly controlled, those who were rapidly controlled but escaped after 6 months  of treatment, those with late control and those who remain uncontrolled during 12 months of treatment. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Clin Kidney J, sfz021, The content of this slide may be subject to copyright: please see the slide notes for details.

5 FIGURE 5 Mean daily cinacalcet-HCl dose in the four groups of different PTH trajectories. This figure shows the daily ... FIGURE 5 Mean daily cinacalcet-HCl dose in the four groups of different PTH trajectories. This figure shows the daily mean dose of cinacalcet-HCl in the four groups of patients with different PTH trajectories. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Clin Kidney J, sfz021, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "FIGURE 1 Flow chart of patient enrollment and exclusion"

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±

FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±
Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.
Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.

Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:
Figure 2. Temperature-entropy diagram and the flow resistances of the power plant model of Figure 1. From: Thermodynamic optimization of a triple-shaft.

Figure 2. Temperature-entropy diagram and the flow resistances of the power plant model of Figure 1. From: Thermodynamic optimization of a triple-shaft.
Figure 3: Full-body skeletal scintigraphy.

Figure 3: Full-body skeletal scintigraphy.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2

Similar presentations

Ads by Google